Tranilast inhibits interleukin-1β-induced monocyte chemoattractant protein-1 expression in rat mesangial cells

Akihiro Chikaraishi, Junichi Hirahashi, Osamu Takase, Takeshi Marumo, Keiichi Hishikawa, Matsuhiko Hayashi, Takao Saruta

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Monocyte chemoattractant protein-1 (MCP-1), a member of the CC subfamily of chemokines, plays a crucial role in the progression of glomerulonephritis by recruitment of monocytes. Tranilast, a clinically used anti-allergic drug, has been demonstrated to have various anti-inflammatory and anti-proliferative effects, and recently has been reported to prevent restenosis after percutaneous transluminal coronary angioplasty. In this study, we investigated whether tranilast inhibits MCP-1 secretion in mesangial cells. Tranilast inhibited interleukin-1β-induced MCP-1 secretion and mRNA expression in a concentration-dependent manner. Luciferase assay showed that tranilast suppressed interleukin-1β-induced nuclear factor-κB (NF-κB)-dependent transcription. Interleukin-1β-induced Jun N-terminal kinase (JNK) activation was also suppressed selectively by tranilast. These results indicate that tranilast inhibits interleukin-1β-induced MCP-1 production, at least in part, by inhibiting NF-κB activity and that suppression of JNK activation might be involved in the inhibition of MCP-1 production. Tranilast may serve as a new therapeutic agent for glomerulonephritis through anti-chemokine property.

Original languageEnglish
Pages (from-to)151-158
Number of pages8
JournalEuropean Journal of Pharmacology
Volume427
Issue number2
DOIs
Publication statusPublished - 2001 Sep 14

Fingerprint

Mesangial Cells
Chemokine CCL2
Interleukin-1
Glomerulonephritis
Phosphotransferases
CC Chemokines
Anti-Allergic Agents
Coronary Balloon Angioplasty
tranilast
Luciferases
Chemokines
Monocytes
Anti-Inflammatory Agents
Messenger RNA
Pharmaceutical Preparations

Keywords

  • MCP-1 (monocyte chemoattractant protein-1)
  • Mesangial cell
  • NF-κB (nuclear factor-κB)
  • Tranilast

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Tranilast inhibits interleukin-1β-induced monocyte chemoattractant protein-1 expression in rat mesangial cells. / Chikaraishi, Akihiro; Hirahashi, Junichi; Takase, Osamu; Marumo, Takeshi; Hishikawa, Keiichi; Hayashi, Matsuhiko; Saruta, Takao.

In: European Journal of Pharmacology, Vol. 427, No. 2, 14.09.2001, p. 151-158.

Research output: Contribution to journalArticle

Chikaraishi, Akihiro ; Hirahashi, Junichi ; Takase, Osamu ; Marumo, Takeshi ; Hishikawa, Keiichi ; Hayashi, Matsuhiko ; Saruta, Takao. / Tranilast inhibits interleukin-1β-induced monocyte chemoattractant protein-1 expression in rat mesangial cells. In: European Journal of Pharmacology. 2001 ; Vol. 427, No. 2. pp. 151-158.
@article{a1c4f48dbc154b9f89c048d4feab4c9e,
title = "Tranilast inhibits interleukin-1β-induced monocyte chemoattractant protein-1 expression in rat mesangial cells",
abstract = "Monocyte chemoattractant protein-1 (MCP-1), a member of the CC subfamily of chemokines, plays a crucial role in the progression of glomerulonephritis by recruitment of monocytes. Tranilast, a clinically used anti-allergic drug, has been demonstrated to have various anti-inflammatory and anti-proliferative effects, and recently has been reported to prevent restenosis after percutaneous transluminal coronary angioplasty. In this study, we investigated whether tranilast inhibits MCP-1 secretion in mesangial cells. Tranilast inhibited interleukin-1β-induced MCP-1 secretion and mRNA expression in a concentration-dependent manner. Luciferase assay showed that tranilast suppressed interleukin-1β-induced nuclear factor-κB (NF-κB)-dependent transcription. Interleukin-1β-induced Jun N-terminal kinase (JNK) activation was also suppressed selectively by tranilast. These results indicate that tranilast inhibits interleukin-1β-induced MCP-1 production, at least in part, by inhibiting NF-κB activity and that suppression of JNK activation might be involved in the inhibition of MCP-1 production. Tranilast may serve as a new therapeutic agent for glomerulonephritis through anti-chemokine property.",
keywords = "MCP-1 (monocyte chemoattractant protein-1), Mesangial cell, NF-κB (nuclear factor-κB), Tranilast",
author = "Akihiro Chikaraishi and Junichi Hirahashi and Osamu Takase and Takeshi Marumo and Keiichi Hishikawa and Matsuhiko Hayashi and Takao Saruta",
year = "2001",
month = "9",
day = "14",
doi = "10.1016/S0014-2999(01)01215-8",
language = "English",
volume = "427",
pages = "151--158",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Tranilast inhibits interleukin-1β-induced monocyte chemoattractant protein-1 expression in rat mesangial cells

AU - Chikaraishi, Akihiro

AU - Hirahashi, Junichi

AU - Takase, Osamu

AU - Marumo, Takeshi

AU - Hishikawa, Keiichi

AU - Hayashi, Matsuhiko

AU - Saruta, Takao

PY - 2001/9/14

Y1 - 2001/9/14

N2 - Monocyte chemoattractant protein-1 (MCP-1), a member of the CC subfamily of chemokines, plays a crucial role in the progression of glomerulonephritis by recruitment of monocytes. Tranilast, a clinically used anti-allergic drug, has been demonstrated to have various anti-inflammatory and anti-proliferative effects, and recently has been reported to prevent restenosis after percutaneous transluminal coronary angioplasty. In this study, we investigated whether tranilast inhibits MCP-1 secretion in mesangial cells. Tranilast inhibited interleukin-1β-induced MCP-1 secretion and mRNA expression in a concentration-dependent manner. Luciferase assay showed that tranilast suppressed interleukin-1β-induced nuclear factor-κB (NF-κB)-dependent transcription. Interleukin-1β-induced Jun N-terminal kinase (JNK) activation was also suppressed selectively by tranilast. These results indicate that tranilast inhibits interleukin-1β-induced MCP-1 production, at least in part, by inhibiting NF-κB activity and that suppression of JNK activation might be involved in the inhibition of MCP-1 production. Tranilast may serve as a new therapeutic agent for glomerulonephritis through anti-chemokine property.

AB - Monocyte chemoattractant protein-1 (MCP-1), a member of the CC subfamily of chemokines, plays a crucial role in the progression of glomerulonephritis by recruitment of monocytes. Tranilast, a clinically used anti-allergic drug, has been demonstrated to have various anti-inflammatory and anti-proliferative effects, and recently has been reported to prevent restenosis after percutaneous transluminal coronary angioplasty. In this study, we investigated whether tranilast inhibits MCP-1 secretion in mesangial cells. Tranilast inhibited interleukin-1β-induced MCP-1 secretion and mRNA expression in a concentration-dependent manner. Luciferase assay showed that tranilast suppressed interleukin-1β-induced nuclear factor-κB (NF-κB)-dependent transcription. Interleukin-1β-induced Jun N-terminal kinase (JNK) activation was also suppressed selectively by tranilast. These results indicate that tranilast inhibits interleukin-1β-induced MCP-1 production, at least in part, by inhibiting NF-κB activity and that suppression of JNK activation might be involved in the inhibition of MCP-1 production. Tranilast may serve as a new therapeutic agent for glomerulonephritis through anti-chemokine property.

KW - MCP-1 (monocyte chemoattractant protein-1)

KW - Mesangial cell

KW - NF-κB (nuclear factor-κB)

KW - Tranilast

UR - http://www.scopus.com/inward/record.url?scp=0035860445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035860445&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(01)01215-8

DO - 10.1016/S0014-2999(01)01215-8

M3 - Article

C2 - 11557268

AN - SCOPUS:0035860445

VL - 427

SP - 151

EP - 158

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2

ER -